US Senators Probe Links Between Opioid Manufacturers and Medical Groups - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

US Senators Probe Links Between Opioid Manufacturers and Medical Groups


ePT--the Electronic Newsletter of Pharmaceutical Technology

Senators Max Baucus (D-MT) and Chuck Grassley (R-IA) are probing ties between manufacturers of opioid painkillers and medical groups that have advocated for increased use of such drugs for pain management. The intent of the probe is to establish the extent of financial ties between the two to determine whether there has been undue influence of industry on prescribing practices. The impetus for the probe is the high rate of abuse of prescription opioids, and the dangers such drugs pose. According to a press release from the two senators, deaths from painkiller overdoses have tripled over the last decade and led to the deaths of 14,800 Americans in 2008, exceeding those caused by heroin and cocaine combined.

Letters were sent to Perdue Pharma, Endo Pharmaceuticals, and Johnson & Johnson, asking them to disclose financial ties to 10 medical groups and eight individuals who played a prominent role in setting pain management guidelines. The companies were also asked to provide all communications in regard to the book Responsible Opioid Prescribing: A Physician's Guide, distributed by the Federation of State Medical Boards, and communications in regard to the pain management guidelines published by several medical groups.

The Senators also sent letters to the American Pain Foundation, the American Academy of Pain Medicine, the American Pain Society, the Center for Practical Bioethics, the Wisconsin Pain and Policy Study Group, the Joint Commission on Accreditation of Healthcare Organizations, and the Federation of State Medical Boards asking them to disclose financial support from any company that develops, manufactures, or distributes opioid pain medications.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here